Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > What I do Like

<< Previous

Bullboard Posts

Next >>

Comment by Alba1314on Aug 27, 2018 10:50am

93 Views

Post# 28522034

RE:RE:RE:RE:RE:RE:RE:RE:RE:What I do Like

I feel your pain scarri. I was stuck for 4 years after iCo-007 failed and the stock I bought in the 0.40's plummeted to $0.04. The thing I like about iCo-008 is it's a reformulation of a drug that is known to work.

Maybe we'll have similar luck: https://en.wikipedia.org/wiki/Cynapsus_Therapeutics

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China